Regeneus (ASX:RGS) - CEO, Leo Lee
CEO, Leo Lee
Source: Regeneus
The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Regenerative medicine company Regeneus (RGS) has received a U.S. patent for Sygenus, a topical serum and gel treatment for pain and inflammation
  • The company received an issue of allowance from the U.S Patent and Trademark Office
  • The patent will cover the treatment of a broad range of non-inflammatory skin conditions
  • Regeneus is up 14.3 per cent on the market this afternoon and is trading for 16 cents per share

Regenerative medicine company Regeneus (RGS) has received a U.S. patent for Sygenus, a topical serum and gel treatment for pain and inflammation.

The company announced today it had received an issue of allowance from the U.S Patent and Trademark Office.

The patent will cover the treatment of a broad range of non-inflammatory skin conditions with adipose-derived cell secretions, including age spots, sun spots, thinning skin, wrinkles and other age-related degenerative diseases.

The patent will cover commercial rights in the U.S. through to 2032.

“This patent will expand the application of our Secretome-only technology platform Sygenus into the US$53 billion-dollar (approximately A$73 billion) Aesthetics Therapeutic market,” CEO and Executive Director Leo Lee said.

“We’re pleased to broaden our intellectual property (IP) portfolio and look forward to applying Sygenus to a broad range of skin conditions,” he added.

Regeneus is up 14.3 per cent on the market this afternoon and is trading for 16 cents per share at 1:00 pm AEST.

RGS by the numbers
More From The Market Herald

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…

Little Green Pharma positions itself for growth in France’s emerging medicinal cannabis market

Little Green Pharma (ASX:LGP) is primed for substantial growth after a major amendment to the French…

PolyNovo posts $8m sales month and $9m revenue month for November

Disruptive medical device company PolyNovo (ASX:PNV) has announced record monthly sales of $8.8 million for November…
Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Imugene (ASX:IMU) is on the verge of securing approval from the European Patent Office (EPO) for…